Highly potent and specific RXR agonist (Kd values 0.4 nM, 3.6 nM, and 3.8 nM for RXRα, RXRβ, and RXRγ, respectively) devoid of any RAR activity (Kd values >30 µM for RARα, RARβ, and RARγ). NRX 194204 blocked the ability of lipopolysaccharide and TNFα to induce the release of nitric oxide and IL6 and the degradation of IKBα in RAW264.7 macrophage-like cells. NRX194204 prevents carcinogenesis in both the lung and mammary gland, and enhances the ability of ligands for PPARs or cytotoxic drugs, including cisplatin and 5-flurouracil, to inhibit proliferation and induce apoptosis in breast and pancreatic cancer cell lines.

KEYWORDS: NRX 194204 | RXR agonist | NRX 4204 | VTP 194204 | AGN 194204 | AGN 4204 | NRX4204 | NRX-4204 | IRX 4204 | IRX-4204 | NRX194204 | NRX-194204 | VTP194204 | VTP-194204 | AGN194204 | AGN-194204 | AGN4204 | AGN-4204 | CAS [220619-73-8] | Retinoic Acid | Retinoic Acid (RXR) | devoid | RAR | carcinogenesis | Agonist | Receptors